Articles Referencing TEVA
Teva's Quartette Approved in the US - Analyst Blog
4/4/2013, 10:08 am from Zacks.com in Investing, Business, Stocks
Teva Pharmaceutical Industries Ltd. ( TEVA ) recently
announced that its 91-day oral contraceptive, Quartette, gained FDA
approval for the prevention of pregnancy. Quartette, a... Read >>
Court Rules Against AstraZeneca - Analyst Blog
4/3/2013, 5:22 pm from Zacks.com in Investing, Business, Stocks
Recently, United States District Court for the District of New
Jersey dealt a blow to AstraZeneca ( AZN ) when it ruled
that a patent (6,598,603) protecting Pulmicort Respules... Read >>
Data on Teva's Azilect - Analyst Blog
3/25/2013, 7:26 pm from Zacks.com in Investing, Business, Stocks
Teva Pharmaceutical ( TEVA ) and H. Lundbeck
A/S recently presented positive data on Azilect from a
double-blind, placebo controlled, randomized, multicenter
study. Teva and H. Lundbeck... Read >>
OncoGenex Loss Lower than Expected - Analyst Blog
3/11/2013, 4:09 pm from Zacks.com in Investing, Business, Stocks
OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported fourth
quarter 2012 net loss per share of 39 cents, narrower than the
Zacks Consensus Estimate of a loss of 49 cents and the year-ago
loss... Read >>
Global Malaise Not Affecting These Countries (Or Companies)
3/11/2013, 12:08 am from GuruFocus in Investing
Yes, there has been a global malaise that began in 2008. (Much
earlier, actually, but 2008 is when someone noticed that the drinks
were being paid for with Monopoly money.) The U.S. Federal... Read >>
Teva Enrolls Patients in MS Study - Analyst Blog
3/8/2013, 3:50 pm from Zacks.com in Investing, Business, Stocks
Teva Pharmaceutical Industries Ltd. ( TEVA ) and Active
Biotech recently announced that the first patient for their phase
III CONCERTO study has been enrolled. The multinational,... Read >>
Patent Relief for Pfizer - Analyst Blog
3/6/2013, 4:15 pm from Zacks.com in Investing, Business, Stocks
Pfizer Inc. ( PFE ) recently received
some good news with the US Patent & Trademark Office granting a
reissue patent for Pfizer's pain drug, Celebrex. Celebrex is
approved for the... Read >>
Coronado Biosciences: 2013 - Year Of The Worm
3/3/2013, 4:08 am from SeekingAlpha in Investing, Stocks
By Iggy Igette : It is indeed the Year of the Worm. Last year I wrote about Coronado Biosciences ( CNDO ) and "The
Hygiene Hypothesis," a theory that explains why exposure... Read >>
These ETFs Have Moving Average Problems
2/27/2013, 3:23 pm from Benzinga in Investing, Commodities, ETFs, Investing Ideas
Let's quickly clear up that headline. Not all of the ETFs that will be
highlighted here have violated a key moving average such as the 50-
or 200-day lines. However, the funds that will be... Read >>
Are Global Health Care ETFs Worth Prescribing?
2/22/2013, 11:24 am from Benzinga in Investing, ETFs, International, Investing Ideas
Conservative investors and risk-takers alike have been rewarded
for owning U.S. health care stocks and ETFs focusing on
those names in recent years. The data supports that assertion. A look... Read >>
Encouraging News at Chelsea - Analyst Blog
2/21/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks
Chelsea Therapeutics International Ltd. ( CHTP ) recently
announced that it received written guidance from the Director of
the Office of New Drugs at the US Food and Drug... Read >>
Gilead and Teva Bury the Hatchet - Analyst Blog
2/21/2013, 1:30 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) recently
settled its dispute with Teva Pharmaceutical Industries
Limited ( TEVA ) regarding the
former's antiviral drug Viread. Viread is marketed for... Read >>
FDA Approves Teva's Generic - Analyst Blog
2/21/2013, 12:30 pm from Zacks.com in Investing, Business, Stocks
Teva Pharmaceutical Industries Ltd. ( TEVA ) recently
announced that it has gained US Food and Drug Administration (FDA)
approval for its generic version of Shire's ( SHPG ) Adderall... Read >>
OncoGenex' Candidate Progresses - Analyst Blog
2/14/2013, 4:50 pm from Zacks.com in Investing, Business, Stocks
OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently
announced that it is looking to move its oncology candidate,
OGX-427, into a phase II study, Borealis-2, for the potential
treatment of... Read >>
Teva Pharmaceutical Industries Limited (TEVA) Ex-Dividend Date Scheduled for February 19, 2013
2/14/2013, 9:00 am from NASDAQ.com News in News Headlines, Stocks
Teva Pharmaceutical Industries Limited ( TEVA ) will begin
trading ex-dividend on February 19, 2013. A cash dividend payment
of $0.31 per share is scheduled to be paid on March 07,... Read >>